Summaries & Associations of Study Results
Levels from TR-543 alpha-Methylstyrene
Target Organs and Levels of Evidence
NTP Technical Report Number 543
Produced from Chemtrack Database 10/17/06
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| ALPHA-METHYLSTYRENE 98-83-9 |
06/12/06 | MONOMER FOR POLY(ALPHA-METHYLSTYRENE). (TDB) | Inhalation R: 0, 100, 300, OR 1000 PPM M: 0, 100, 300, OR 600 PPM; 50/SEX/SPECIES | Battelle Northwest Laboratory |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: SOME EVIDENCE | KIDNEY: ADENOMA (STANDARD EVALUATION) 0/50 0/50 1/50 0/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 2/50 5/50 ADENOMA OR CARCINOMA (STANDARD EVALUATION) 0/50 0/50 2/50 2/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 3/50 7/50 | |||
| MAY HAVE BEEN RELATED: | MONONUCLEAR CELL LEUKEMIA: 26/50 32/50 29/50 38/50 | |||
| NON-NEOPLASTIC LESIONS: | KIDNEY: PAPILLA MINERALIZATION; TUBULAR HYPERPLASIA | |||
| NASAL CAVITY: EPITHELIAL HYPERPLASIA; BASAL CELL EPITHELIAL DEGENERATION | ||||
| FR: NO EVIDENCE | ||||
| NON-NEOPLASTIC LESIONS: | NASAL CAVITY: EPITHELIAL HYPERPLASIA; BASAL CELL EPITHELIAL DEGENERATION | |||
| MM: EQUIVOCAL EVIDENCE | ||||
| MAY HAVE BEEN RELATED: | LIVER: ADENOMA OR CARCINOMA 28/50 36/50 33/50 37/50 | |||
| NON-NEOPLASTIC LESIONS: | NASAL CAVITY: EPITHELIAL METAPLASIA; BOWNAM'S GLANDS HYPERPLASIA, ATROPHY | |||
| FM: CLEAR EVIDENCE | LIVER: ADENOMA 10/50 20/50 21/50 23/50 CARCINOMA 3/50 9/50 6/50 18/50 ADENOMA OR CARCINOMA 13/50 26/50 24/50 33/50 | |||
| NON-NEOPLASTIC LESIONS: | LIVER: EOSINOPHILIC FOCUS | |||
| NASAL CAVITY: EPITHELIAL METAPLASIA; BOWMAN'S GLANDS HYPERPLASIA | ||||
| KIDNEY: NEPHROPATHY, SEVERITY OF NEPHROPATHY | ||||
Web page last updated on January 23, 2008
